Beta společnosti Neovacs S.A
Jaká je hodnota metriky Beta společnosti Neovacs S.A?
Hodnota metriky Beta společnosti Neovacs S.A. je 0.82
Jaká je definice metriky Beta?
BETA koeficient vyjadřuje, zda je akcie více či méně volatilní než trh jako celek. Beta menší než 1 znamená, že akcie jsou méně volatilní než trh, zatímco beta větší než 1 znamená, že akcie jsou volatilnější. Volatilita se měří pomocí fluktuace ceny akcie.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta společností v sektoru Health Care sektor na EURONEXT ve srovnání se společností Neovacs S.A
Čemu se věnuje společnost Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Firmy s metrikou beta podobnou společnosti Neovacs S.A
- Hodnota metriky Beta společnosti Rubfila International je 0.82
- Hodnota metriky Beta společnosti TeamViewer AG je 0.82
- Hodnota metriky Beta společnosti TeamViewer AG je 0.82
- Hodnota metriky Beta společnosti TeamViewer AG je 0.82
- Hodnota metriky Beta společnosti Willis Towers Watson Public Co je 0.82
- Hodnota metriky Beta společnosti Mineworx Technologies je 0.82
- Hodnota metriky Beta společnosti Neovacs S.A je 0.82
- Hodnota metriky Beta společnosti Tri-Continental je 0.82
- Hodnota metriky Beta společnosti Sichuan Investment Development Co je 0.82
- Hodnota metriky Beta společnosti Yahoo Japan je 0.82
- Hodnota metriky Beta společnosti Mahindra Holidays & Resorts India je 0.82
- Hodnota metriky Beta společnosti Zhongsheng je 0.82
- Hodnota metriky Beta společnosti Shanghai Dasheng Agriculture Finance Technology Co je 0.82